User:Mr. Ibrahem/Cerliponase alfa
 Structure of tripeptidyl peptidase 1 (TPP1) enzyme for which cerliponase alfa is a replacement | |
| Clinical data | |
|---|---|
| Trade names | Brineura |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intraventricular |
| Drug class | Enzyme[1] |
| Legal status | |
| Legal status |
|
| Chemical and physical data | |
| Formula | C2657H4042N734O793S11 |
| Molar mass | 59308.2298 g·mol−1 |
Cerliponase alfa, marketed as Brineura, is a medication used to treat late infantile neuronal ceroid lipofuscinosis type 2 (CLN2).[2] In symptomatic children over three years old it slows loss of muscle function.[2] It is given by direct infusion into the ventricles of the brain.[1][3]
Common side include fever, vomiting, headache,seizures, upper respiratory tract infection, and allergic reactions.[1][2] Other side effects may include arrhythmias, meningitis, and anaphylaxis.[2] It works by replacing the missing enzyme tripeptidyl peptidase 1 (TPP1).[1]
Cerliponase alfa was approved for medical use in the United States and Europe in 2017.[2][1] In Canada it costs about 844,000 CAD per year as of 2019.[4] In the United States this amount costs about 710,000 USD.[5]
References[edit]
- ^ a b c d e f "Brineura". Archived from the original on 14 November 2021. Retrieved 3 January 2022.
- ^ a b c d e f "DailyMed - BRINEURA- cerliponase alfa kit". dailymed.nlm.nih.gov. Archived from the original on 23 March 2021. Retrieved 3 January 2022.
- ^ "Cerliponase Alfa Monograph for Professionals". Drugs.com. Archived from the original on 10 December 2019. Retrieved 3 January 2022.
- ^ "Pharmacoeconomic Review Report" (PDF). CADTH. Archived (PDF) from the original on 19 October 2019. Retrieved 3 January 2022.
- ^ "Cerliponase Alfa Prices and Cerliponase Alfa Coupons - GoodRx". GoodRx. Retrieved 3 January 2022.